- Home
- ZENV vs EPIX Comparison
ZENV vs EPIX Comparison
Compare ZENV & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- EPIX
- Stock Information
- Founded
- ZENV 2005
- EPIX 2009
- Country
- ZENV Brazil
- EPIX Canada
- Employees
- ZENV N/A
- EPIX N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- EPIX Health Care
- Exchange
- ZENV Nasdaq
- EPIX Nasdaq
- Market Cap
- ZENV 79.7M
- EPIX 75.9M
- IPO Year
- ZENV 2021
- EPIX N/A
- Fundamental
- Price
- ZENV $1.56
- EPIX $0.24
- Analyst Decision
- ZENV
- EPIX Hold
- Analyst Count
- ZENV 0
- EPIX 3
- Target Price
- ZENV N/A
- EPIX $2.00
- AVG Volume (30 Days)
- ZENV 33.5K
- EPIX 14.7M
- Earning Date
- ZENV 09-10-2025
- EPIX 08-13-2025
- Dividend Yield
- ZENV N/A
- EPIX N/A
- EPS Growth
- ZENV N/A
- EPIX N/A
- EPS
- ZENV N/A
- EPIX N/A
- Revenue
- ZENV $181,911,572.00
- EPIX N/A
- Revenue This Year
- ZENV $6.49
- EPIX N/A
- Revenue Next Year
- ZENV $3.82
- EPIX N/A
- P/E Ratio
- ZENV N/A
- EPIX N/A
- Revenue Growth
- ZENV 23.99
- EPIX N/A
- 52 Week Low
- ZENV $1.02
- EPIX $0.22
- 52 Week High
- ZENV $3.03
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- ZENV 49.46
- EPIX 6.03
- Support Level
- ZENV $1.53
- EPIX $0.23
- Resistance Level
- ZENV $1.64
- EPIX $0.26
- Average True Range (ATR)
- ZENV 0.10
- EPIX 0.02
- MACD
- ZENV -0.01
- EPIX -0.09
- Stochastic Oscillator
- ZENV 54.50
- EPIX 0.87
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.